We Will Cure Releases Longevity Biotech Clinical Trials Map Through 2027
On August 25, the editorial project We Will Cure published a map of longevity biotech clinical trials planned through 2027. It aligns programs that have already begun human studies, obtained initial data, or are preparing the next stage. By the end of 2027 they will answer whether humans tolerate the intervention, whether it affects the targeted process, and whether there is grounds to expand the trial.
Companies test aging‑biology ideas through concrete diseases and quantifiable
🔗 Read original →
PubMed Central (PMC)
Recommendations for biomarker data collection in clinical trials by longevity biotechnology companies
Biomarkers of aging have the potential to transform geroscience clinical trials because of their broad applications in stratifying participants, prioritizing interventions, and monitoring responses to geroprotectors. As longevity biotechnology ...
